No Data
No Data
Rhythm Pharmaceuticals Says EMA Committee Backs Expanded Authorization for Obesity Drug
Rhythm Pharmaceuticals (RYTM) said Friday it had received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending an expanded marketing aut
Rhythm Says European Medicines Agency's CHMP Adopted Positive Opinion Recommending Marketing Authorization For IMCIVREE; European Commission Decision Anticipated In H2 Of 2024
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization for IMCIVREE (setmelanotide) include
Express News | Rhythm Pharmaceuticals Inc - European Commission Decision Anticipated in Second Half of 2024
Express News | Rhythm Pharmaceuticals Receives Positive Chmp Opinion for ▼Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old With Bardet Biedl Syndrome or Pomc, Pcsk1, or Lepr Deficiency
Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Harmony Biosciences
DelveInsight's Obesity Market Insights report includes a comprehensive understanding of current treatment practices, obesity emerging drugs, market...
What Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) P/S Is Not Telling You
With a price-to-sales (or "P/S") ratio of 28x Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) may be sending very bearish signals at the moment, given that almost half of all the Biotechs companies in the